These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 37800801)

  • 21. Change in MRI-PDFF and Histologic Response in Patients With Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis.
    Stine JG; Munaganuru N; Barnard A; Wang JL; Kaulback K; Argo CK; Singh S; Fowler KJ; Sirlin CB; Loomba R
    Clin Gastroenterol Hepatol; 2021 Nov; 19(11):2274-2283.e5. PubMed ID: 32882428
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease.
    Park CC; Nguyen P; Hernandez C; Bettencourt R; Ramirez K; Fortney L; Hooker J; Sy E; Savides MT; Alquiraish MH; Valasek MA; Rizo E; Richards L; Brenner D; Sirlin CB; Loomba R
    Gastroenterology; 2017 Feb; 152(3):598-607.e2. PubMed ID: 27911262
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Irisin in patients with nonalcoholic fatty liver disease.
    Polyzos SA; Kountouras J; Anastasilakis AD; Geladari EV; Mantzoros CS
    Metabolism; 2014 Feb; 63(2):207-17. PubMed ID: 24140091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Accuracy and Clinical Relevance of the Multi-echo Dixon Technique for Evaluating Changes to Hepatic Steatosis in Patients with Non-alcoholic Fatty Liver Disease Treated with Formulated Food.
    Yang Y; Xu K; Chen X; Ding J; Shi J; Li J
    Magn Reson Med Sci; 2023 Apr; 22(2):263-271. PubMed ID: 35676065
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib.
    Jayakumar S; Middleton MS; Lawitz EJ; Mantry PS; Caldwell SH; Arnold H; Mae Diehl A; Ghalib R; Elkhashab M; Abdelmalek MF; Kowdley KV; Stephen Djedjos C; Xu R; Han L; Mani Subramanian G; Myers RP; Goodman ZD; Afdhal NH; Charlton MR; Sirlin CB; Loomba R
    J Hepatol; 2019 Jan; 70(1):133-141. PubMed ID: 30291868
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease.
    Harrison SA; Baum SJ; Gunn NT; Younes ZH; Kohli A; Patil R; Koziel MJ; Chera H; Zhao J; Chakravarthy MV
    Am J Gastroenterol; 2021 Dec; 116(12):2399-2409. PubMed ID: 34382947
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlations Between MRI Biomarkers PDFF and cT1 With Histopathological Features of Non-Alcoholic Steatohepatitis.
    Dennis A; Kelly MD; Fernandes C; Mouchti S; Fallowfield JA; Hirschfield G; Pavlides M; Harrison S; Chakravarthy MV; Banerjee R; Sanyal A
    Front Endocrinol (Lausanne); 2020; 11():575843. PubMed ID: 33584535
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of Quantitative Imaging Biomarkers for Early-phase Clinical Trials of Steatohepatitis in Adolescents.
    Goyal NP; Sawh MC; Ugalde-Nicalo P; Angeles JE; Proudfoot JA; Newton KP; Middleton MS; Sirlin CB; Schwimmer JB
    J Pediatr Gastroenterol Nutr; 2020 Jan; 70(1):99-105. PubMed ID: 31633654
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Definitions of Normal Liver Fat and the Association of Insulin Sensitivity with Acquired and Genetic NAFLD-A Systematic Review.
    Petäjä EM; Yki-Järvinen H
    Int J Mol Sci; 2016 Apr; 17(5):. PubMed ID: 27128911
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liver fat quantification: where do we stand?
    Starekova J; Reeder SB
    Abdom Radiol (NY); 2020 Nov; 45(11):3386-3399. PubMed ID: 33025153
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial.
    Guo W; Tian W; Lin L; Xu X
    Diabetes Res Clin Pract; 2020 Dec; 170():108487. PubMed ID: 33035599
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes mellitus: one year results from the first international, open-label, prospective, multicentre study.
    van Baar ACG; Holleman F; Crenier L; Haidry R; Magee C; Hopkins D; Rodriguez Grunert L; Galvao Neto M; Vignolo P; Hayee B; Mertens A; Bisschops R; Tijssen J; Nieuwdorp M; Guidone C; Costamagna G; Devière J; Bergman JJGHM
    Gut; 2020 Feb; 69(2):295-303. PubMed ID: 31331994
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma Fibroblast Growth Factor 21 Is Associated With Severity of Nonalcoholic Steatohepatitis in Patients With Obesity and Type 2 Diabetes.
    Barb D; Bril F; Kalavalapalli S; Cusi K
    J Clin Endocrinol Metab; 2019 Aug; 104(8):3327-3336. PubMed ID: 30848827
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prospective, Same-Day, Direct Comparison of Controlled Attenuation Parameter With the M vs the XL Probe in Patients With Nonalcoholic Fatty Liver Disease, Using Magnetic Resonance Imaging-Proton Density Fat Fraction as the Standard.
    Caussy C; Brissot J; Singh S; Bassirian S; Hernandez C; Bettencourt R; Rizo E; Richards L; Sirlin CB; Loomba R
    Clin Gastroenterol Hepatol; 2020 Jul; 18(8):1842-1850.e6. PubMed ID: 31843596
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multicenter Validation of Association Between Decline in MRI-PDFF and Histologic Response in NASH.
    Loomba R; Neuschwander-Tetri BA; Sanyal A; Chalasani N; Diehl AM; Terrault N; Kowdley K; Dasarathy S; Kleiner D; Behling C; Lavine J; Van Natta M; Middleton M; Tonascia J; Sirlin C;
    Hepatology; 2020 Oct; 72(4):1219-1229. PubMed ID: 31965579
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease.
    Alexopoulos AS; Crowley MJ; Wang Y; Moylan CA; Guy CD; Henao R; Piercy DL; Seymour KA; Sudan R; Portenier DD; Diehl AM; Coviello AD; Abdelmalek MF
    Hepatology; 2021 Sep; 74(3):1220-1233. PubMed ID: 33724511
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis.
    Patel J; Bettencourt R; Cui J; Salotti J; Hooker J; Bhatt A; Hernandez C; Nguyen P; Aryafar H; Valasek M; Haufe W; Hooker C; Richards L; Sirlin CB; Loomba R
    Therap Adv Gastroenterol; 2016 Sep; 9(5):692-701. PubMed ID: 27582882
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatic Alanine Differentiates Nonalcoholic Steatohepatitis From Simple Steatosis in Humans and Mice: A Proton MR Spectroscopy Study With Long Echo Time.
    Kim TH; Jun HY; Kim KJ; Lee YH; Lee MS; Choi KH; Yun KJ; Jeong YY; Jun CH; Cho EY; Yoon KH
    J Magn Reson Imaging; 2017 Nov; 46(5):1298-1310. PubMed ID: 28225569
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Utility of MR proton density fat fraction and its correlation with ultrasonography and biochemical markers in nonalcoholic fatty liver disease in overweight adolescents.
    Netaji A; Jain V; Gupta AK; Kumar U; Jana M
    J Pediatr Endocrinol Metab; 2020 Apr; 33(4):473-479. PubMed ID: 32146441
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adipokines and C-reactive protein in relation to bone mineralization in pediatric nonalcoholic fatty liver disease.
    Pacifico L; Bezzi M; Lombardo CV; Romaggioli S; Ferraro F; Bascetta S; Chiesa C
    World J Gastroenterol; 2013 Jul; 19(25):4007-14. PubMed ID: 23840146
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.